Serum Dehydroepiandrosterone sulfate (DHEA-S) level and its potential impact on immune responses and symptom severity after Oxford-AstraZeneca COVID-19 vaccination.

Abbasifard, M ; Dehghan Banadaki, M ; et al.

In: International immunopharmacology, Jg. 133 (2024-05-30), S. 112057

Online academicJournal

Zugriff:

Zum Volltext

Background: Dehydroepiandrosterone sulfate (DHEA-S) has been associated with an immunomodulatory function. This study aims to explore the relationship between serum levels of DHEA-S and the immune responses triggered by the Oxford-AstraZeneca COVID-19 vaccine in individuals candidate for vaccination.

Methods: Serum levels of DHEA-S, cytokine release, antibody production and virus neutralization potential were assessed in 50 male and 50 female subjects before and 2 weeks after vaccination with Oxford-AstraZeneca COVID-19 vaccine.

Results: Level of DHEA-S before and 2 weeks after first and second dose of vaccination was not different significantly. Levels of Interleukin (IL)-2 and Interferon (IFN)-γ were significantly higher in the supernatant of peripheral blood mononuclear cells (PBMCs) obtained from subjects 2 weeks after both first and second dose of vaccination compared to before vaccination. Serum levels of IgM 2 weeks after first dose of vaccination was significantly higher compared to before first dose of vaccination. However, serum levels of IgG 2 weeks after first and second dose of vaccination were significantly higher compared to before first and second dose of vaccination. The 50 % focus reduction neutralization test (FRNT 50 ) titer was significantly higher 2 weeks after both first and second dose of vaccination compared to before vaccination. Levels of DHEA-S did not have significant correlation with levels of IL-2, IFN-γ, IgM and IgG, and FRNT 50 before and after first and second dose of vaccination. Vaccination did not result in intense unwanted clinical presentations.

Conclusion: DHEA-S is not involved in the quality of protective immune response during Oxford-AstraZeneca COVID-19 vaccination.

Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Titel:	Serum Dehydroepiandrosterone sulfate (DHEA-S) level and its potential impact on immune responses and symptom severity after Oxford-AstraZeneca COVID-19 vaccination.
Autor/in / Beteiligte Person:	Abbasifard, M ; Dehghan Banadaki, M ; Taghipour Khaje Sharifi, G ; Rahnama, A ; Bagheri-Hosseinabadi, Z
Link:	Zum Volltext
Zeitschrift:	International immunopharmacology, Jg. 133 (2024-05-30), S. 112057
Veröffentlichung:	Amsterdam ; New York : Elsevier Science, c2001-, 2024
Medientyp:	academicJournal
ISSN:	1878-1705 (electronic)
DOI:	10.1016/j.intimp.2024.112057
Schlagwort:	Humans Male Female Adult Middle Aged Antibodies, Viral blood Vaccination Leukocytes, Mononuclear immunology Interferon-gamma blood Immunoglobulin G blood Antibodies, Neutralizing blood Cytokines blood Dehydroepiandrosterone Sulfate blood COVID-19 immunology COVID-19 prevention & control COVID-19 blood COVID-19 Vaccines immunology COVID-19 Vaccines administration & dosage SARS-CoV-2 immunology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Int Immunopharmacol] 2024 May 30; Vol. 133, pp. 112057. <i>Date of Electronic Publication: </i>2024 Apr 13. MeSH Terms: Dehydroepiandrosterone Sulfate* / blood ; COVID-19* / immunology ; COVID-19* / prevention & control ; COVID-19* / blood ; COVID-19 Vaccines* / immunology ; COVID-19 Vaccines* / administration & dosage ; SARS-CoV-2* / immunology ; Humans ; Male ; Female ; Adult ; Middle Aged ; Antibodies, Viral / blood ; Vaccination ; Leukocytes, Mononuclear / immunology ; Interferon-gamma / blood ; Immunoglobulin G / blood ; Antibodies, Neutralizing / blood ; Cytokines / blood Contributed Indexing: Keywords: COVID-19; DHEA-S; Protective antibody; SARS-CoV-2 Substance Nomenclature: 57B09Q7FJR (Dehydroepiandrosterone Sulfate) ; 0 (COVID-19 Vaccines) ; 0 (Antibodies, Viral) ; 82115-62-6 (Interferon-gamma) ; 0 (Immunoglobulin G) ; 0 (Antibodies, Neutralizing) ; 0 (Cytokines) Entry Date(s): Date Created: 20240414 Date Completed: 20240511 Latest Revision: 20240511 Update Code: 20240512

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.